Benitec Biopharma Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BNTC | SLDB | PRQR | ABEO | DTIL | DSGN | |
|---|---|---|---|---|---|---|
| Market cap | 316.39M | 719.48M | 228.61M | 280.20M | 180.24M | 682.77M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.0 | -3.9 | -3.4 | -23.6 | -3.5 | -6.7 |
| Price/book | 1.8 | 1.9 | 2.6 | 2.2 | 3.8 | 3.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −40.87% | +14.31% | −28.82% | −8.41% | +20.86% | +79.51% |
| Today | +2.25% | −2.33% | −0.61% | −0.81% | −2.83% | −6.35% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BNTC news ›Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
The BB-301 pivotal trial remains on track to begin in mid-2027Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including…
Benitec Biopharma Inc. Stock 12‑Month Price Target Raised to $24.33, Implies 171% Upside
TradingView Benitec Biopharma Inc. Stock 12‑Month Price Target Raised to $24.33, Implies 171% Upside - According to estimates from 6 analysts, Benitec Biopharma Inc. stock's average price target has risen from $23.2 to $24.33, with…
Benitec Biopharma says BB-301 pivotal trial on track to start mid-2027 after FDA Type C feedback
TradingView Benitec Biopharma says BB-301 pivotal trial on track to start mid-2027 after FDA Type C feedback Benitec Biopharma reported that FDA feedback after a Type C meeting keeps the BB-301 pivotal study on track to begin mid-2027. -…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tradingview.com4
-
manilatimes.net1
-
sci-tech-today.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.